Press Release: Enveric Biosciences Announces Closing Of Exercise Of Warrants For $3.1 Million Gross Proceeds

Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Industrials, Basic Materials and Healthcare sectors led shares higher.

At the close in NYSE, the Dow Jones Industrial Average gained 1.05%, while the S&P 500 index climbed 0.68%, and the NASDAQ Composite index climbed 0.33%.

The best performers of the session on the Dow Jones Industrial Average were Nike Inc (NYSE:NKE), which rose 3.91% or 2.48 points to trade at 65.81 at the close. Meanwhile, Caterpillar Inc (NYSE:CAT) added 3.53% or 20.99 points to end at 615.35 and Johnson & Johnson (NYSE:JNJ) was up 3.29% or 6.58 points to 206.54 in late trade.

The worst performers of the session were Microsoft Corporation (NASDAQ:MSFT), which fell 2.78% or 13.70 points to trade at 478.56 at the close. Walmart Inc (NASDAQ:WMT) declined 1.66% or 1.91 points to end at 113.15 and Boeing Co (NYSE:BA) was down 0.82% or 1.65 points to 198.72.

The top performers on the S&P 500 were GE Vernova LLC (NYSE:GEV) which rose 15.59% to 722.77, Celanese Corporation (NYSE:CE) which was up 7.60% to settle at 43.26 and Western Digital Corporation (NASDAQ:WDC) which gained 7.32% to close at 181.95.

The worst performers were Uber Technologies Inc (NYSE:UBER) which was down 5.51% to 84.16 in late trade, Netflix Inc (NASDAQ:NFLX) which lost 4.15% to settle at 92.69 and HCA Holdings Inc (NYSE:HCA) which was down 4.05% to 468.73 at the close.

The top performers on the NASDAQ Composite were Beasley Broadcast Group Inc (NASDAQ:BBGI) which rose 302.17% to 16.69, Heartbeam Inc (NASDAQ:BEAT) which was up 94.29% to settle at 1.57 and Enveric Biosciences Inc (NASDAQ:ENVB) which gained 73.31% to close at 10.26.

The worst performers were Work Medical Technology Group Ltd (NASDAQ:WOK) which was down 96.59% to 0.19 in late trade, Agape ATP Corp (NASDAQ:ATPC) which lost 94.85% to settle at 0.07 and PomDoctor Ltd ADR (NASDAQ:POM) which was down 90.77% to 0.50 at the close.

Rising stocks outnumbered declining ones on the New York Stock Exchange by 1925 to 821 and 91 ended unchanged; on the Nasdaq Stock Exchange, 2119 rose and 1266 declined, while 167 ended unchanged.

Shares in GE Vernova LLC (NYSE:GEV) rose to all time highs; rising 15.59% or 97.47 to 722.77. Shares in Western Digital Corporation (NASDAQ:WDC) rose to all time highs; rising 7.32% or 12.41 to 181.95. Shares in Caterpillar Inc (NYSE:CAT) rose to all time highs; rising 3.53% or 20.99 to 615.35. Shares in Beasley Broadcast Group Inc (NASDAQ:BBGI) rose to 52-week highs; up 302.17% or 12.54 to 16.69. Shares in Work Medical Technology Group Ltd (NASDAQ:WOK) fell to all time lows; down 96.59% or 5.38 to 0.19. Shares in Agape ATP Corp (NASDAQ:ATPC) fell to all time lows; falling 94.85% or 1.25 to 0.07. Shares in PomDoctor Ltd ADR (NASDAQ:POM) fell to all time lows; losing 90.77% or 4.92 to 0.50.

The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 6.85% to 15.77.

Gold Futures for February delivery was up 0.49% or 20.75 to $4,256.95 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 1.17% or 0.68 to hit $58.93 a barrel, while the February Brent oil contract rose 1.11% or 0.69 to trade at $62.63 a barrel.

EUR/USD was up 0.58% to 1.17, while USD/JPY fell 0.47% to 156.04.

The US Dollar Index Futures was down 0.56% at 98.64.

Investing.com -- Enveric Biosciences (NASDAQ:ENVB) stock surged 103% in premarket trading Wednesday after the biotechnology company announced it received a Notice of Allowance from the United States Patent and Trademark Office for a patent application related to its EVM301 Series of molecules.

The patent, titled "N-heterocycle substituted tryptamine derivatives and methods of using," will expand Enveric’s portfolio of patents for its EVM301 Series, which is being developed to treat mental health disorders. This allowance strengthens the company’s intellectual property position around potential neuroplastogenic non-hallucinogenic molecules targeting neuropsychiatric and addiction disorders.

The USPTO issues a Notice of Allowance after determining a patent should be granted from an application. The compositions claims and methods of use claims covered by this patent will further broaden Enveric’s pipeline and reinforce protection for its therapeutic candidates.

"We continue to work diligently to reinforce our patent estate around our lead asset, EB-003 and the EVM301 Series of compounds, which we see as vital in order to generate value for Enveric shareholders," said Joseph Tucker, Ph.D., Director and CEO of Enveric.

The company is developing EB-003 as a compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting antidepressant and anxiolytic effects. According to Tucker, the compound is specifically designed to promote neuroplasticity while minimizing hallucinogenic effects, potentially allowing for administration in outpatient settings.

Enveric Biosciences focuses on developing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.